Abstract 23P
Background
Immune checkpoint inhibitors (IO) combinations are standard in metastatic renal cell carcinoma (mRCC) but validated biomarkers are lacking to guide strategies towards either dual IO or IO plus tyrosine kinase inhibitors (TKI). Circulating immune cells (CIC) may inform antitumor immune response but have been mostly studied with IO monotherapy. We aimed at exploring the association between CIC and outcomes in mRCC patients treated with IO including combinations.
Methods
Phenotyping of peripheral blood mononuclear cells was performed by flow cytometry before systemic treatment in PREMIS (NCT03984318) and NIVOREN trials (NCT03013335). CIC included T cells (total CD8+, senescent CD8+, total CD4+, senescent CD4+) and B cells (naive, naive transitional, switched and unswitched memory, double negative, plasmablasts) subpopulations. We assessed associations between CIC and objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) across treatment subgroups. An exploratory analysis of CIC and tissue immune infiltrate was conducted.
Results
Among 112 patients, median age was 61 y.o; 75% had clear cell histology, 64% intermediate/poor risk disease. Regimens included IO-TKI in 28%, dual IO in 15%, IO monotherapy in 54%. A lower proportion of CD8+ T cells was associated with improved ORR in the overall population (p=0.008), and improved ORR (p=0.002) and PFS (HR 0.6, p=0.030) in patients treated with IO monotherapy or dual IO. No association between T cells and outcomes in patients treated with IO-TKI was observed. Senescent CD8+ T cells were highly associated with CD8+ T cell levels (r=0.51, p<0.001), and inversely associated with the presence of tertiary lymphoid structures or lymphoid aggregates within the tumor. Among B cells, plasmablasts were inversely associated with ORR (p=0.019) in the overall population with no impact on survival. Across treatment regimens, B cell subtypes were only predictive in IO monotherapy, with switched memory B cells associated with improved ORR (p=0.014) and PFS (HR 0.54, p=0.020).
Conclusions
Circulating CD8+ T cells and CD8+ senescence may inform resistance to dual IO but not IO-TKI. The role of B cells warrants further investigation. Longitudinal analyses are ongoing.
Clinical trial identification
NCT03013335, NCT03984318.
Legal entity responsible for the study
The authors.
Funding
French National Cancer Institute, ARC Foundation, Artur Foundation.
Disclosure
R. Flippot: Financial Interests, Institutional, Funding: Bayer; Financial Interests, Personal, Invited Speaker: Astellas, Janssen, MSD; Financial Interests, Personal, Non-financial benefits: BMS; Financial Interests, Personal, Speaker, Consultant, Advisor: Ipsen, Pfizer. B. Escudier: Financial Interests, Personal, Financially compensated role: Ipsen, Pfizer, Oncorena, Aveo, BMS, Ipsen; Financial Interests, Personal and Institutional, Research Funding: BMS. L. Albiges: Financial Interests, Institutional, Other, Consulting: Astellas, BMS, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche, Merck; Financial Interests, Personal, Other, Honoraria: Novartis; Non-Financial Interests, Personal, Principal Investigator, Clinical trial steering committee: Pfizer, BMS, AVEO, AstraZeneca, MSD; Non-Financial Interests, Personal, Principal Investigator: Ipsen; Non-Financial Interests, Personal, Other, Clinical trial steering committee: Roche, Exelixis; Non-Financial Interests, Personal, Member: ASCO; Non-Financial Interests, Personal, Other, Medical Steering Committee: Kidney Cancer Association; Non-Financial Interests, Personal, Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology (EAU). All other authors have declared no conflicts of interest.
Resources from the same session
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display
60P - Adaptive NK cells as a therapeutic option for childhood leukaemia
Presenter: Zoya Eskandarian
Session: Poster Display